Lonicera Innovation research is focused on developing a new approach directed towards prevention of disease, or on reversing early stages of disease. The intestinal microorganisms (the microbiota) have a profound influence on human health,
Type 2 Diabetes
The Lonicera approach on Type 2 Diabetes (T2D) is based on the robust understanding of the benefits of probiotics in diabetes at the cellular level, in both animal studies and clinical trials, based on their excellent tolerability record.
Current data from a clinical study on patients with colon cancer demonstrated that the Lonicera Tablet Matrix was successful on delivering more than 85% of each tablet bacteria load, in a viable state to a targeted area in the gut. The probiotic remedy used for this trial,